Zinc

The height gain is a standardised effect of 0.12, which is real across a population and invisible in any one child. The diarrhoea figure came from 19,468 children while the mortality analyses carried over 130,000 each, which is part of why the nulls in this review are the more certain results. The trials ran mostly in low- and middle-income countries where zinc shortage is common.

The children were mostly under five, in low- and middle-income countries, on 10 to 15 mg of zinc a day for a median of 26 weeks, so this is not evidence about supplementing a well-fed child anywhere else. The review's own summary describes zinc as probably reducing deaths from chest infection and from malaria, but both of those ranges cross into no effect and the authors add that they could not rule out an increased risk of death. A null on mortality is not a null on everything the same trials measured.

Nine trials and 1,449 people, graded low certainty. The review pooled lozenges, syrups, tablets and nasal gels as one treatment, with the gluconate lozenge doses alone spanning 45 to 276 mg a day. It also excluded any product mixing zinc with other vitamins or herbs, which is most of what a pharmacy actually sells.

The figure comes from roughly a week of high-dose lozenges taken during a cold, not from a daily supplement taken for months. It counts non-serious events only, and no treatment study recorded a serious one. Sixteen trials contributed, most at unclear or high risk of bias in at least one area.

Most of these trials ran in Asian countries where zinc shortage is common, and the review's authors say plainly that the evidence does not support giving zinc to well-nourished children or in low-risk settings. Vomiting rose in both age groups, by about 57% in the over-sixes, which is a real cost in a child already losing fluid. Death and hospitalisation, the outcomes that matter most, sit at very low certainty and are not settled here.

Neither finding comes from a trial designed to test the pairing: one is a subgroup pattern and the other a set of marker outcomes graded very low to moderate certainty. The usual explanation, that two similar metals compete for the same route into the body, is not tested by either source. All of it concerns children given substantial doses of both minerals in settings where deficiency is common, not the small amounts in a multivitamin.

The notice is careful about what it did and did not establish: the duplicated text was judged minor and correctable, and the data allegation was investigated and left inconclusive, which is not a finding of misconduct. The complainant is himself the author of the competing review that the withdrawal left standing. The withdrawal covers the 2013 version specifically.

These are null results in very small groups: three acetate trials against four gluconate ones, and five lower-dose trials against two higher-dose. Failing to show a difference in 575 people is not the same as showing there is none, and the ranges are wide enough to hide a real one in either direction. Every trial used lozenges in adults with ordinary colds, so none of it reaches children, prevention, or any other route.

This comes from a narrative review written as a call to action, so it argues a position rather than weighing evidence neutrally, with no stated search strategy or bias assessment. Two of its authors work for an organisation promoting biofortification, one of the solutions the paper recommends. Its own link between zinc and blood sugar or heart risk is described as growing evidence rather than established, and should not be read as settled.

Every outcome here is a laboratory marker rather than an illness, so this shows zinc moving numbers, not children coming to harm. The authors say outright that whether the findings matter clinically is unclear, and the certainty runs from very low to moderate. Each adverse finding held in at least one subgroup rather than across the board, so none of it describes a general effect of a stated dose.

A label is a regulatory and marketing document, not evidence: the pack's stated purpose of reducing cold duration is a manufacturer claim made under the homeopathic route, not one a regulator reviewed. Nothing here says the product does or does not reach the dose the trials used, only that the label does not let you check. This is the oral tablet, a different product from the nasal gels that drew the smell-loss reports.

Neither source was designed to test the pairing: one is a set of marker outcomes graded very low to moderate certainty, the other an absence noted while setting an intake limit. The child trials used substantial doses of both minerals in populations where deficiency is common, not the amounts in an ordinary multivitamin. And the panel's finding was recorded in 2001 and has not been revisited.

A US panel found no evidence of clinically significant harm from iron and zinc interacting; pooled trials in under-threes saw zinc move iron markers the wrong way. Neither set out to test the pairing, so whether to space them is unknown.

Fifty people in the primary trial, which reported colds 44% shorter, far above anything the wider literature supports. That trial is one of the three inside the pooled analysis, so the two are not independent confirmations of each other. The finding that the effect held regardless of allergy, smoking, age or gender rests on those same 199 people, too few for that comparison to carry weight.

Eight trials, 972 people. The estimate mixes zinc acetate, gluconate and orotate given as lozenges, syrups and tablets, so it is an average over treatments that may not behave alike. Most of the included studies carried an unclear or high risk of bias in at least one area.

Zinc lozenge trials scatter widely. One reading says that makes any effect size untrustworthy; another sees a dose split, nothing below about 75 mg a day and a great deal above. No trial has split them, so how much zinc helps is open.

Thirty-seven cases gathered over 53 years have no denominator, so nothing here says how likely this is at any dose, and case reports get published because they are striking. The zinc came from denture adhesive cream and swallowed coins as well as supplements, so not every dose in that range is a supplement dose. A single case at 50 mg a day is not evidence that 50 mg a day is generally unsafe.

Adverse-event reports are voluntary and unverified, so 130 counts reports received rather than confirmed cases, and it cannot be turned into a risk per user in either direction. The causality analysis is a structured argument rather than a controlled study, and it comes from the same clinic and senior author as the case series it draws on. All of it concerns the nasal gel: lozenges and tablets are a different product taken a different way, with no comparable evidence of smell loss.

The 75 mg line was drawn after looking at the data rather than set in advance, so it explains the same trials it came from. Five trials below it and eight above is a thin basis for a threshold. Both reviews behind it have the same single author, whose complaint is what got the competing Cochrane review withdrawn.

The zinc came with 5 mg of folic acid a day and there was no zinc-only arm, so neither result can be pinned on the zinc by itself. The men were fertile and subfertile patients at a fertility clinic, not chosen for their zinc status, so this shows what happens when you supplement a mixed group rather than a group known to have enough. Eighty-seven men across four arms is thin enough that this is an effect not detected rather than an effect ruled out.

Eleven men, and every arm of the study sat at or below the 11 mg of zinc a day a man is meant to get, so it compares degrees of going short and never tests giving anyone extra. Thirty-five days at each intake says nothing about years at one. Nothing here shows that a man who already has enough zinc gains anything from more.

How far zinc shortage lowers testosterone is unsettled. An uncontrolled study of four men reported a 73% fall; a controlled feeding study that cut zinc far lower saw 19%. The weaker design produced the figure that travelled.

An upper limit is a population ceiling for long-term intake from all sources, not the dose at which harm begins in a person. The short lozenge regimens that shortened colds ran at 80 to 92 mg of zinc a day and exceeded it deliberately, for about a week, which is not an error in either the trials or the limit. The US figure was set in 2001 and has not been revised for zinc since.

Europe caps zinc at 25 mg a day and the US at 40, from the same copper evidence. No new data separates them, only a judgement on how much copper loss is acceptable, and nothing settles which reading is right.

The restriction arm reported a 73% fall in testosterone from what the paper itself calls marginal restriction, larger than the controlled feeding study found at a far lower intake, which is an anomaly rather than a detail. The supplementation arm recruited men already identified as zinc deficient, so it cannot speak to anyone else. Alongside both sits a correlation measured in 40 men, and a correlation in 40 people is where this began.